Piramal Of India Cleared For Phase II Trial Of Cancer Molecule
This article was originally published in PharmAsia News
India's Piramal Life Sciences says it is about to begin a Phase II trial of its P276 molecule for head and neck cancers. The treatment proved successful a Phase I trial conducted in Canada. The company noted the extra time it takes to get Indian approval, usually six months versus an average of 28 days in developed countries, and said it has been waiting since February for approval. (Click here for more
You may also be interested in...
The FAST 01 feasibility trial is evaluating a modification to Varian’s ProBeam particle accelerator that enables ultra-high dose radiation to treat cancer.
AstraZeneca's research head admits that half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
HBW Insight speaks to new Global Self-Care Federation chair and Bayer CH chief Heiko Schipper about the role that self-care can play in alleviating pressure on national health care systems, the importance of self-care's scientific credentials and of maintaining supply chain continuity during the coronavirus pandemic.